Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTX [NASD]
Nkarta, Inc.
Index- P/E- EPS (ttm)-3.47 Insider Own1.00% Shs Outstand16.81M Perf Week-12.07%
Market Cap1.08B Forward P/E- EPS next Y-2.96 Insider Trans-8.59% Shs Float10.75M Perf Month-23.26%
Income-91.40M PEG- EPS next Q-0.53 Inst Own84.20% Short Float22.17% Perf Quarter-41.04%
Sales- P/S- EPS this Y-684.80% Inst Trans0.90% Short Ratio9.25 Perf Half Y-2.34%
Book/sh19.11 P/B1.64 EPS next Y-28.10% ROA-47.20% Target Price- Perf Year-
Cash/sh9.13 P/C3.42 EPS next 5Y- ROE-67.80% 52W Range22.46 - 79.16 Perf YTD-49.16%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.52% Beta-
Dividend %- Quick Ratio36.10 Sales past 5Y- Gross Margin- 52W Low39.14% ATR3.06
Employees95 Current Ratio36.10 Sales Q/Q- Oper. Margin- RSI (14)35.08 Volatility9.25% 9.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-53.70% Profit Margin- Rel Volume0.48 Prev Close32.51
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume257.64K Price31.25
Recom1.80 SMA20-9.09% SMA50-28.09% SMA200-20.70% Volume122,850 Change-3.88%
Aug-04-20Initiated Stifel Buy $41
Aug-04-20Initiated Mizuho Buy $34
Aug-04-20Initiated Evercore ISI Outperform $55
Aug-04-20Initiated Cowen Outperform
Mar-25-21 04:03PM  
Feb-17-21 04:03PM  
Dec-09-20 03:46PM  
Dec-07-20 03:33PM  
Nov-12-20 04:03PM  
04:02PM  
Nov-09-20 08:02AM  
Nov-05-20 04:02PM  
Oct-12-20 11:03AM  
Oct-05-20 04:02PM  
Sep-29-20 08:02AM  
Sep-08-20 04:02PM  
Aug-20-20 04:02PM  
Jul-31-20 04:42PM  
Jul-14-20 04:39PM  
04:15PM  
Jul-10-20 11:30AM  
08:09AM  
12:44AM  
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahmood NadirSee RemarksApr 01Option Exercise3.893,50013,61534,988Apr 02 03:59 PM
Mahmood NadirSee RemarksApr 01Sale32.703,500114,45031,488Apr 02 03:59 PM
HASTINGS PAUL JChief Executive OfficerMar 30Sale30.7417,000522,540236,061Apr 01 06:15 AM
Trager JamesChief Scientific OfficerFeb 02Option Exercise18.002,80050,40049,872Feb 03 07:48 PM
Trager JamesChief Scientific OfficerFeb 02Sale40.002,800112,00047,072Feb 03 07:48 PM
Trager JamesChief Scientific OfficerFeb 01Option Exercise3.892,2508,75250,672Feb 03 07:48 PM
Trager JamesChief Scientific OfficerFeb 01Sale38.673,600139,22947,072Feb 03 07:48 PM
Mahmood NadirSee RemarksJan 25Option Exercise3.895,50021,39536,988Jan 26 04:10 PM
Mahmood NadirSee RemarksJan 25Sale48.575,500267,12031,488Jan 26 04:10 PM
Mahmood NadirSee RemarksJan 14Option Exercise3.893,08311,99331,488Jan 19 10:06 AM
Mahmood NadirSee RemarksDec 03Option Exercise3.893,00011,67028,405Dec 07 08:27 PM
Flynn James EPossible Member of 10% GroupJul 14Buy18.001,000,00018,000,0001,209,936Jul 14 11:39 AM
Florence Anthony A. Jr.10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
BASKETT FOREST10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
MAKOWER JOSHUA10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Makhzoumi Mohamad10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Sonsini Peter W.10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
SANDELL SCOTT D10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
New Enterprise Associates 15, 10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Novo Holdings A/S10% OwnerJul 14Buy18.00555,5559,999,9902,793,865Jul 16 04:41 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJul 14Buy18.003,333,33359,999,9945,605,129Jul 16 04:30 PM
GLAXOSMITHKLINE PLCDirectorJul 14Buy18.00833,33314,999,9943,150,732Jul 16 08:13 PM